1. Academic Validation
  2. Expression dynamics of integrin α2, α3, and αV upon osteogenic differentiation of human mesenchymal stem cells

Expression dynamics of integrin α2, α3, and αV upon osteogenic differentiation of human mesenchymal stem cells

  • Stem Cell Res Ther. 2020 Jun 3;11(1):210. doi: 10.1186/s13287-020-01714-7.
Hyun Min Lee 1 Se-Ri Seo 1 Jeeseung Kim 1 Min Kyu Kim 1 Hyosun Seo 1 Kyoung Soo Kim 2 Young-Joo Jang 3 Chun Jeih Ryu 4
Affiliations

Affiliations

  • 1 Department of Integrative Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, 05006, Korea.
  • 2 Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul, 02447, Korea.
  • 3 Department of Nanobiomedical Science, BK21 PLUS NBM Global Research Center for Regenerative Medicine, College of Dentistry, Dankook University, Cheonan, 330-714, Korea. [email protected].
  • 4 Department of Integrative Bioscience and Biotechnology, Institute of Anticancer Medicine Development, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, 05006, Korea. [email protected].
Abstract

Background: The differentiation of human mesenchymal stem cells (hMSCs) into osteoblasts (OBs) is a prerequisite for bone formation. However, little is known about the definitive surface markers for OBs during osteogenesis.

Methods: To study the surface markers on OBs, we generated and used monoclonal Antibodies (MAbs) against surface molecules on transforming growth factor-β1 (TGF-β1)-treated Cancer cells. The generated MAbs were further selected toward expression changes on hMSCs cultured with TGF-β1/bone morphogenetic protein-2 (BMP-2) or osteogenic differentiation medium (ODM) by flow cytometry. Immunoprecipitation and mass spectrometry were performed to identify target antigens of selected MAbs. Expression changes of the target antigens were evaluated in hMSCs, human periodontal ligament cells (hPDLCs), and human dental pulp cells (hDPCs) during osteogenic and adipogenic differentiation by quantitative polymerase chain reaction (qPCR) and flow cytometry. hMSCs were also sorted by the MAbs using magnetic-activated cell sorting system, and osteogenic potential of sorted cells was evaluated via Alizarin Red S (ARS) staining and qPCR.

Results: The binding reactivity of MR14-E5, one of the MAbs, was downregulated in hMSCs with ODM while the binding reactivity of ER7-A7, ER7-A8, and MR1-B1 MAbs was upregulated. Mass spectrometry and overexpression identified that MR14-E5, ER7-A7/ER7-A8, and MR1-B1 recognized Integrin α2, α3, and αV, respectively. Upon osteogenic differentiation of hMSCs, the expression of Integrin α2 was drastically downregulated, but the expression of Integrin α3 and αV was upregulated in accordance with upregulation of osteogenic markers. Expression of Integrin α3 and αV was also upregulated in hPDLCs and hDPCs during osteogenic differentiation. Cell sorting showed that Integrin αV-high hMSCs have a greater osteogenic potential than Integrin αV-low hMSCs upon the osteogenic differentiation of hMSCs. Cell sorting further revealed that the surface expression of Integrin αV is more dramatically induced even in Integrin αV-low hMSCs.

Conclusion: These findings suggest that Integrin α3 and αV induction is a good indicator of OB differentiation. These findings also shed insight into the expression dynamics of integrins upon osteogenic differentiation of hMSCs and provide the reason why different Integrin ligands are required for OB differentiation of hMSCs.

Keywords

Human mesenchymal stem cells; Integrin α2; Integrin α3; Integrin αV; Monoclonal antibodies; Osteoblasts; Osteogenic differentiation.

Figures
Products